Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications

R Hirawat, MA Saifi, C Godugu - Life sciences, 2021 - Elsevier
Such testing and trying time probably never seen before in the human history. The novel
coronavirus disease abbreviated as COVID-19 is the ongoing health crisis which entered …

Early differences in cytokine production by severity of coronavirus disease 2019

LH Tjan, K Furukawa, T Nagano, T Kiriu… - The Journal of …, 2021 - academic.oup.com
Most patients with coronavirus disease 2019 (COVID-19) experience asymptomatic disease
or mild symptoms, but some have critical symptoms requiring intensive care. It is important to …

T cell immunobiology and cytokine storm of COVID‐19

XH Luo, Y Zhu, J Mao, RC Du - Scandinavian journal of …, 2021 - Wiley Online Library
Abstract 2019 coronavirus disease (COVID‐19) presents as a newly recognized pneumonia
and could rapidly progress into acute respiratory distress syndrome which has brought …

[HTML][HTML] Macrophage activation syndrome and COVID-19

R Otsuka, K Seino - Inflammation and regeneration, 2020 - Springer
An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating
pandemic. As we have not developed curative medicine and effective vaccine, the end of …

An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis

Y Liu, D Chen, J Hou, H Li, D Cao, M Guo, Y Ling… - Cytokine, 2021 - Elsevier
The hyper-inflammatory response is thought to be a major cause of acute respiratory
distress syndrome (ARDS) in patients with COVID-19. Although multiple cytokines are …

[HTML][HTML] Preemptive interleukin-6 blockade in patients with COVID-19

L Guillén, S Padilla, M Fernández, V Agulló… - Scientific Reports, 2020 - nature.com
Excessive interleukin-6 signaling is a key factor contributing to the cytokine release
syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that …

[HTML][HTML] Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

G Zhou, S Chen, Z Chen - Frontiers of medicine, 2020 - Springer
Since the outbreak of the COVID-19 pandemic in early December 2019, 81 174 confirmed
cases and 3242 deaths have been reported in China as of March 19, 2020. The Chinese …

[HTML][HTML] Why tocilizumab could be an effective treatment for severe COVID-19?

B Fu, X Xu, H Wei - Journal of translational medicine, 2020 - Springer
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …

[HTML][HTML] Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia

A Santa Cruz, A Mendes-Frias, AI Oliveira… - Frontiers in …, 2021 - frontiersin.org
Hyper-inflammatory responses induced by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) are a major cause of disease severity and death. Predictive prognosis …

[HTML][HTML] Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm?

L Lu, H Zhang, M Zhan, J Jiang, H Yin… - Frontiers in Cell and …, 2020 - frontiersin.org
Coronavirus disease 2019 (COVID-19) from severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection has resulted in tremendous morbidity and mortality worldwide. A …